Int. J. Mol. Sci. 2014, 15(4), 6062-6071; doi:10.3390/ijms15046062

Asymmetric Dimethylarginine in Chronic Obstructive Pulmonary Disease (ADMA in COPD)

1email, 2email, 3email, 4email, 2email and 4,* email
Received: 30 December 2013; in revised form: 7 March 2014 / Accepted: 31 March 2014 / Published: 10 April 2014
(This article belongs to the Special Issue ADMA and Nitrergic System)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: l-Arginine metabolism including the nitric oxide (NO) synthase and arginase pathways is important in the maintenance of airways function. We have previously reported that accumulation of asymmetric dimethylarginine (ADMA) in airways, resulting in changes in l-arginine metabolism, contributes to airways obstruction in asthma and cystic fibrosis. Herein, we assessed l-arginine metabolism in airways of patients with chronic obstructive pulmonary disease (COPD). Lung function testing, measurement of fractional exhaled NO (FeNO) and sputum NO metabolites, as well as quantification of l-arginine metabolites (l-arginine, l-ornithine, l-citrulline, ADMA and symmetric dimethylarginine) using liquid chromatography-mass spectrometry (LC-MS) were performed. Concentrations of l-ornithine, the product of arginase activity, correlated directly with l-arginine and ADMA sputum concentrations. FeNO correlated directly with pre- and post-bronchodilator forced expiratory volume in one second (FEV1). Sputum arginase activity correlated inversely with total NO metabolite (NOx) and nitrite concentrations in sputum, and with pre- and post-bronchodilator FEV1. These findings suggest that ADMA in COPD airways results in a functionally relevant shift of l-arginine breakdown by the NO synthases towards the arginase pathway, which contributes to airway obstruction in these patients.
Keywords: arginine metabolism; nitric oxide; asymmetric dimethylarginine; arginase; pulmonary function; airway obstruction; l-ornithine
PDF Full-text Download PDF Full-Text [428 KB, uploaded 19 June 2014 05:35 CEST]

Export to BibTeX |

MDPI and ACS Style

Scott, J.A.; Duongh, M.; Young, A.W.; Subbarao, P.; Gauvreau, G.M.; Grasemann, H. Asymmetric Dimethylarginine in Chronic Obstructive Pulmonary Disease (ADMA in COPD). Int. J. Mol. Sci. 2014, 15, 6062-6071.

AMA Style

Scott JA, Duongh M, Young AW, Subbarao P, Gauvreau GM, Grasemann H. Asymmetric Dimethylarginine in Chronic Obstructive Pulmonary Disease (ADMA in COPD). International Journal of Molecular Sciences. 2014; 15(4):6062-6071.

Chicago/Turabian Style

Scott, Jeremy A.; Duongh, MyLinh; Young, Aaron W.; Subbarao, Padmaja; Gauvreau, Gail M.; Grasemann, Hartmut. 2014. "Asymmetric Dimethylarginine in Chronic Obstructive Pulmonary Disease (ADMA in COPD)." Int. J. Mol. Sci. 15, no. 4: 6062-6071.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert